Next Article in Journal
Re. Multimodality Breast Cancer Screening in Women with a Familial or Genetic Predisposition
Previous Article in Journal
Screening for Hepatitis B Surface Antigen before Chemotherapy: Current Practice and Opportunities for Improvement
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue 6
10.3747/co.v17i6.670
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Consensus Recommendations for the Use of Anti-EGFR Therapies in Metastatic Colorectal Cancer

by
C. Cripps
1,
Sharlene Gill
2,3,*,
S. Ahmed
4,
B. Colwell
5,
S. Dowden
3,
H. Kennecke
2,
J. Maroun
1,
B. Samson
6,
M. Thirlwell
7 and
R. Wong
8
1
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
2
Saskatchewan Cancer Agency, Saskatoon, SK, Canada
3
British Columbia Cancer Agency, 600 10th Avenue West, Vancouver, BC V5Z 4E6, Canada
4
QEII Health Sciences Centre, Halifax, NS, Canada
5
Tom Baker Cancer Centre, Calgary, AB, Canada
6
Hôpital Charles LeMoyne, Greenfield Park, QC, Canada
7
McGill University Health Centre, Montreal, QC, Canada
8
CancerCare Manitoba, Winnipeg, MB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(6), 39-45; https://doi.org/10.3747/co.v17i6.670
Submission received: 4 August 2010 / Revised: 14 September 2010 / Accepted: 13 October 2010 / Published: 1 November 2010

Abstract

In January 2010, a panel of Canadian oncologists with particular expertise in colorectal cancer (CRC) gathered to develop a consensus guideline on the use of therapies against the epidermal growth factor receptor (EGFR) in the management of metastatic CRC (MCRC). This paper uses a case-based approach to summarize the consensus recommendations developed during that meeting. These are the consensus recommendations: 1. Testing for the KRAS status of the tumour should be performed as soon as an EGFR inhibitor is being considered as an option for treatment. 2. Anti-EGFR therapies are not recommended for the treatment of patients with tumours showing mutated KRAS status. 3. For a patient with wild-type KRAS and an Eastern Cooperative Oncology Group status of 0–2, whose mCRC has previously been treated with a fluoropyrimidine, irinotecan, and oxaliplatin, switching to an EGFR inhibitor is a recommended strategy. 4. Cetuximab, cetuximab plus irinotecan, and panitumumab are all options for third-line therapy in patients with wild-type KRAS, provided that tolerability is acceptable.
Keywords: Anti-EGFR; metastatic colorectal cancer; cetuximab; panitumumab; Canadian consensus Anti-EGFR; metastatic colorectal cancer; cetuximab; panitumumab; Canadian consensus

Share and Cite

MDPI and ACS Style

Cripps, C.; Gill, S.; Ahmed, S.; Colwell, B.; Dowden, S.; Kennecke, H.; Maroun, J.; Samson, B.; Thirlwell, M.; Wong, R. Consensus Recommendations for the Use of Anti-EGFR Therapies in Metastatic Colorectal Cancer. Curr. Oncol. 2010, 17, 39-45. https://doi.org/10.3747/co.v17i6.670

AMA Style

Cripps C, Gill S, Ahmed S, Colwell B, Dowden S, Kennecke H, Maroun J, Samson B, Thirlwell M, Wong R. Consensus Recommendations for the Use of Anti-EGFR Therapies in Metastatic Colorectal Cancer. Current Oncology. 2010; 17(6):39-45. https://doi.org/10.3747/co.v17i6.670

Chicago/Turabian Style

Cripps, C., Sharlene Gill, S. Ahmed, B. Colwell, S. Dowden, H. Kennecke, J. Maroun, B. Samson, M. Thirlwell, and R. Wong. 2010. "Consensus Recommendations for the Use of Anti-EGFR Therapies in Metastatic Colorectal Cancer" Current Oncology 17, no. 6: 39-45. https://doi.org/10.3747/co.v17i6.670

APA Style

Cripps, C., Gill, S., Ahmed, S., Colwell, B., Dowden, S., Kennecke, H., Maroun, J., Samson, B., Thirlwell, M., & Wong, R. (2010). Consensus Recommendations for the Use of Anti-EGFR Therapies in Metastatic Colorectal Cancer. Current Oncology, 17(6), 39-45. https://doi.org/10.3747/co.v17i6.670

Article Metrics

Back to TopTop